scholarly journals Sedation, Analgesia, and Muscle Relaxation During VV-ECMO Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2): A Single-Center, Retrospective, Observational Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Fang Wu ◽  
Mingna Li ◽  
Zhongwei Zhang ◽  
Jiawei Shang ◽  
Yong Guo ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Observational Study ◽  
Muscle Relaxant ◽  
Muscle Relaxation ◽  
Demographic Data ◽  
Muscle Relaxants ◽  
Single Center ◽  
Optimal Dosing ◽  
Vv Ecmo

Objective: The pharmacokinetics and pharmacodynamics of ECMO-supported sedative, analgesic, and muscle relaxants have changed, but there are insufficient data to determine the optimal dosing strategies for these agents. Sedation, analgesia and muscle relaxation therapy for patients with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) receiving ECMO support are more specific and have not been fully reported. This study observed and evaluated the use of sedative and analgesic drugs and muscle relaxants in SARS-CoV-2 patients treated with VV-ECMO.Methods: This study was a single-center, retrospective and observational study. Our study includes 8 SARS-CoV-2 patients treated with VV-ECMO in an intensive care unit at Shanghai Public Health Center from February to June 2020. We collected the demographic data from these patients and the dose and course of sedation, analgesia, and muscle relaxants administered during ECMO treatment.Results: The doses of sedative, analgesic and muscle relaxant drugs used in patients with VV-ECMO were significant. Over time, the doses of drugs that were used were increased, and the course of muscle relaxant treatment was extended.Conclusion: Sedation, analgesia, and muscle relaxant use require individualized titration in patients with SARS-CoV-2 who have respiratory failure and who are receiving VV-ECMO.

scholarly journals Characteristics of Kawasaki Disease Patients during the COVID-19 Pandemic in Japan: A Single-Center, Observational Study

Children ◽  
2021 ◽  
Vol 8 (10) ◽  
pp. 913
Author(s):  
Shoichi Shimizu ◽  
Mamoru Ayusawa ◽  
Hidetoshi Go ◽  
Kimitaka Nakazaki ◽  
Hidemasa Namiki ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Observational Study ◽  
Retrospective Cohort ◽  
Clinical Characteristics ◽  
Macrophage Activation Syndrome ◽  
Macrophage Activation ◽  
Single Center ◽  
Present Stage ◽  
Single Center Observational Study

Background: Under the Coronavirus disease 2019 (COVID-19) pandemic, manifestations in children with Kawasaki disease (KD) are different between the Western and the Eastern countries. Particularly, there has not been a report comparing a series of KD in Japan, where KD was originally discovered and has a large number of registered cases. Methods: We compared patients with KD under the period of the COVID-19 pandemic in Japan with the report from Italy during its reported period by a retrospective, cohort, observational study in a Japanese single center. Results: Thirty-two patients with typical KD were treated during the study period, while the Italian study reported 10 patients with the signs of KD. Concerning the proof of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, none (0%) of our KD cases showed a positive result and one and no patients developed the macrophage activation syndrome (MAS) and Kawasaki disease shock syndrome (KDSS), respectively; however, eight (80%) patients in the Italian series were confirmed with SARS-CoV-2 infection. MAS and KDSS developed in six and five patients, respectively. Conclusions: Cases reported as COVID-19 pandemic-related KD in Italy showed significantly different clinical characteristics from the typical KD symptoms known in Japan. Although they show KD-like manifestations, we cannot conclude that SARS-CoV-2 has the same etiology of our ‘classic‘ KD at the present stage.

scholarly journals Strokovno stališče Združenja za anesteziologijo in intenzivno medicino o uporabi sugamadeksa

2018 ◽  
Vol 87 (5-6) ◽  
Author(s):  
Neva Požar Lukanović ◽  
Dragan Dević ◽  
Rajko Kandare ◽  
Dušan Mekiš ◽  
Vesna Novak Janković ◽  
...  
Keyword(s):  
Muscle Relaxant ◽  
Muscle Relaxation ◽  
Position Statement ◽  
Muscle Relaxants ◽  
Drug Of Choice ◽  
Strength Recovery ◽  
Muscular Disease ◽  
Objective Control ◽  
Different Response ◽  
Short Time

We present our position statement for the use of sugammadex, a specific binder for aminosteroid muscle relaxants, in the most common clinical circumstances (in the case of an emergency intubation, when the patient cannot be ventilated or intubated; in patients with neuro-muscular disease, in patients with liver failure, in patients with renal failure, in patients with allergic reaction to sugammadex or to rocuronium, in cases of residual muscle relaxation and when we have to use a muscle relaxant short time after sugammadex application). Sugammadex is the drug of choice in cases of cardiac arhythmia, COPD, asthma, neuro-muscular diseases, pathological obesity, intraoperative use of continuous infusion of aminoglycoside muscle relaxants. It is therefore necessary to control the neuro-muscular block during surgery due to different response of patients to the muscle relaxant. Clinical tests alone are not an adequate substitute for objective control of muscular strength recovery.

scholarly journals Computer Controlled Muscle Relaxation: A Comparison of Four Muscle Relaxants in the Sheep

1976 ◽  
Vol 4 (1) ◽  
pp. 16-22 ◽  
Author(s):  
N. M. Cass ◽  
D. G. Lampard ◽  
W. A. Brown ◽  
J. R. Coles
Keyword(s):  
Clinical Practice ◽  
Muscle Relaxant ◽  
Muscle Relaxation ◽  
Computer Control ◽  
Muscle Relaxants ◽  
Muscle Paralysis ◽  
Precise Control ◽  
Integrated Electromyogram ◽  
Computer Controlled

Computer control of anaesthesia has been extended to include muscle relaxant drugs. Injection of d-tubocurarine, gallamine, alcuronium or pancuronium was controlled by computer to reduce the integrated electromyogram to a preset level (40 per cent of control) for one hour. A programmed level of muscle paralysis is therefore possible for use in physiological and pharmacological experiments, and in clinical practice where precise control of the degree of paralysis together with minimal dosage is advantageous.

scholarly journals A study to evaluate the skeletal muscle relaxant property of Pregabalin and Gabapentin in albino rats

2019 ◽  
Vol 8 (6) ◽  
pp. 1381 ◽  
Author(s):  
Sushma V. Naidu ◽  
Vibha Rani
Keyword(s):  
Skeletal Muscle ◽  
Muscle Relaxant ◽  
Muscle Relaxation ◽  
Statistical Significance ◽  
Muscle Relaxants ◽  
Control Group ◽  
Albino Rats ◽  
Skeletal Muscle Relaxant ◽  
Significant Difference ◽  
Group 5

Background: Skeletal muscle relaxants are the drugs which reduce unwanted spasm without interfering with consciousness and voluntary movements. The centrally acting muscle relaxants like Diazepam, is known to be GABA mimetics and other antiepileptics like Gabapentin and Pregabalin also act through the release of GABA. This study is done to investigate skeletal muscle relaxant property of these drugs in comparison to Diazepam.Methods: T Models used in the experiment are Grip Strength Test, Rota Rod Method, Beam Walk Test, Photoactometer Test. Animals were divided into 6 groups of 6 rats each: Group 1: Control group treated with normal saline (0.1 ml/10gm), Group 2: Standard-15mg/kg of Diazepam, Group 3:T1-60 mg/kg of Gabapentin, Group 4:T2-10 mg/kg of Pregabalin, Group 5:T3-60 mg/kg of Gabapentin+Diazepam, Group 6:T4- 10 mg/kg of Pregabalin+Diazepam. Mean and standard deviation was calculated for each group. One way ANOVA was used for multiple group comparisons followed by post hoc Tukey’s test for statistical significance between the groups.Results: Treatment with the above test drugs produced significant muscle relaxation and caused decreased fall off, sliding time, increase climbing time and decreased locomotor activity in all models indicating motor incoordination. The results obtained from both standard and test groups showed a highly significant difference in muscle relaxation when compared with the control group.Conclusions: The test drugs showed skeletal muscle relaxant property in rats comparable to Diazepam. In view of these results, it can open a new avenue for these drugs to be used as skeletal muscle relaxants after conducting clinical trials.

Sign in / Sign up

Export Citation Format

Share Document